A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract - Trial NCT05868265
Access comprehensive clinical trial information for NCT05868265 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Memorial Sloan Kettering Cancer Center
Timeline & Enrollment
Phase 2
Jun 02, 2023
May 01, 2025
Primary Outcome
Proportion of patients who achieve pathologic complete response
Summary
The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an
 effective and safe treatment for people who have urothelial carcinoma of the upper urinary
 tract. Study participants will be people who are not eligible to receive or have chosen not
 to receive the chemotherapy drug cisplatin for treatment of their cancer. In addition, all
 participants will be planning on having standard surgery to remove their tumor.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05868265
Non-Device Trial